Solodyn Generic Delay Class Action Settlement
You are a member of the class if at any time from July 23, 2009 until February 25, 2018, you purchased or paid for some or all of the purchase price for 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg Solodyn and/or its generic versions of one or more of these dosages, in Alabama, Alaska, Arizona, Arkansas, California, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming, the District of Columbia and Puerto Rico, in tablet form, for consumption by yourself or your family.
Proof of Purchase
While at the time there is no POP requirement don’t be surprised if the class action administrator asks for evidence of purchase post-submission
In re: Solodyn (Minocycline Hydrochloride) Antitrust LitigationCase No. 1:14-md-02503
U.S. District Court for the District of Massachusetts
The lawsuit alleges Defendants, delayed the availability of an allegedly less-expensive generic version through allegedly anticompetitive agreements with the other Defendants. Plaintiffs (those who brought the suit) allege that Defendants did so through the unlawful settlement of patent lawsuits in which the patents covering Solodyn were in dispute. Plaintiffs claim that Defendants’ actions denied End-Payors who paid for Solodyn® the benefits of competition and caused them to pay higher prices for Solodyn® than they otherwise would have.
Defendants deny these claims and deny they did anything wrong. No court or other authority has found that Defendants engaged in any wrongdoing. This notice is not an expression of any opinion by the Court as to the merits of Plaintiffs’ claims or the defenses asserted by Defendants.